TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06425380

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistant Potato Starch
Description: Participants will receive 4 weeks of resistant potato starch 20 grams (g) twice daily. Bob's Red Mill® potato starch will be used. Every patient will receive the same dose and there are no dose titrations.
Study: NCT04120285

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: remote internet-based cognitive behavior therapy (eCBT)
Description: Provide access to online psychotherapy program to participants in rural WV areas at no expense to them.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: remote internet-based cognitive behavior therapy (eCBT)
Description: Provide access to online psychotherapy program to participants in rural WV areas at no expense to them.
Study: NCT05188586

Intervention type: OTHER
Group type: OTHER
Intervention: MRI/Imaging
Description: Blood collection and pancreatic cancer early detection testing with return of results.
Study: NCT06579768

Intervention type: DIAGNOSTIC_TEST
Intervention: different types of computed tomography (CT) scans
Description: For enrolled patients with jaw cystic lesions, depending on their group, either a maxillofacial spiral CT scan or a cone beam CT scan is performed before surgical treatment.

Intervention type: DIAGNOSTIC_TEST
Intervention: different types of computed tomography (CT) scans
Description: For enrolled patients with jaw cystic lesions, depending on their group, either a maxillofacial spiral CT scan or a cone beam CT scan is performed before surgical treatment.
Study: NCT04742556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3011441
Description: BI 3011441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3011441
Description: BI 3011441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3011441
Description: BI 3011441
Study: NCT05108246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-Task Exercise Training
Description: Simultaneous cognitive-motor training
Study: NCT06584539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eco-Labels
Description: Eco-labels will be displayed next to more sustainable restaurant menu items. The labels will display an earth icon and the words ENVIRONMENTALLY FRIENDLY.
Study: NCT04993859

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive Urodynamic Test (niUDS)
Description: A noninvasive urodynamics is a simple test used to evaluate urinary flow.

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive Urodynamic Test (niUDS)
Description: A noninvasive urodynamics is a simple test used to evaluate urinary flow.

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive Urodynamic Test (niUDS)
Description: A noninvasive urodynamics is a simple test used to evaluate urinary flow.

Intervention type: DIAGNOSTIC_TEST
Intervention: Non-invasive Urodynamic Test (niUDS)
Description: A noninvasive urodynamics is a simple test used to evaluate urinary flow.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary proteomic screen
Description: Urine proteomics is a powerful platform to identify urinary excreted proteins and peptides in different stages of disease or therapy and to determine their quantity, functions, and interaction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary proteomic screen
Description: Urine proteomics is a powerful platform to identify urinary excreted proteins and peptides in different stages of disease or therapy and to determine their quantity, functions, and interaction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary proteomic screen
Description: Urine proteomics is a powerful platform to identify urinary excreted proteins and peptides in different stages of disease or therapy and to determine their quantity, functions, and interaction.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary proteomic screen
Description: Urine proteomics is a powerful platform to identify urinary excreted proteins and peptides in different stages of disease or therapy and to determine their quantity, functions, and interaction.

Intervention type: OTHER
Intervention: Dysfunctional Voiding Symptom Score Survey (DVSS)
Description: The Dysfunctional Voiding Symptom Score provides accurate and objective grading of voiding behaviors of children.

Intervention type: OTHER
Intervention: Dysfunctional Voiding Symptom Score Survey (DVSS)
Description: The Dysfunctional Voiding Symptom Score provides accurate and objective grading of voiding behaviors of children.

Intervention type: OTHER
Intervention: Dysfunctional Voiding Symptom Score Survey (DVSS)
Description: The Dysfunctional Voiding Symptom Score provides accurate and objective grading of voiding behaviors of children.

Intervention type: OTHER
Intervention: Dysfunctional Voiding Symptom Score Survey (DVSS)
Description: The Dysfunctional Voiding Symptom Score provides accurate and objective grading of voiding behaviors of children.
Study: NCT05746611

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Mycobacterium tuberculosis fusion protein for injection
Description: For the suction test, EC0.1ml was injected into the palmar skin of the forearm by the Mondu's method

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Mycobacterium tuberculosis fusion protein for injection
Description: For the suction test, EC0.1ml was injected into the palmar skin of the forearm by the Mondu's method

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TB-PPD was injected
Description: For the aspiration test, 0.1ml TB-PPD was injected into the palmar skin of the forearm by the Mondu's method
Study: NCT05766397

Intervention type: DRUG
Group type: OTHER
Intervention: Methoxyflurane
Description: Methoxyflurane belongs to the fluorinated hydrocarbon group of volatile anesthetic gases
Study: NCT06475664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized legal care services
Description: Participants will receive free, personalized legal care services from Cancer Legal Care (CLC), a nonprofit organization located in the Twin Cities of Minnesota. The duration of study participation is 6 months, however, participants may continue to access free personalized legal care services beyond this period.
Study: NCT05397717

Intervention type: OTHER
Intervention: observational
Description: Observational, without interfering the patient care of treating doctors
Study: NCT06448273

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3702 tablets
Description: TQB3702 tablets is administered as a single dose on day 1, or once daily on Days 1 to 7 on multiple dose. Dosage: 100mg, 150/200mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQB3702 placebo
Description: TQB3702 placebo contains no active substance.
Study: NCT06279026

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UTAA17 Injection
Description: After signing informed consent, subjects will be screened according to inclusion/exclusion criteria. Successful subjects will receive 3E8 CAR+γδT, 5E8 CAR+γδT, 1E9 CAR+γδT, 5E9 CAR+γδT, 1E10 CAR+γδT cell transfusions in sequence, and each subject will receive only one dose.
Study: NCT06352723

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: Study Drug: Cenobamate 400mg x 1 NGT/G-tube (Day 1), 100mg (Day 2-14)~* Discontinued cenobamate upon cessation of seizures or RegiSCAR score 4-5 or at 14 days.~* Adjust cenobamate dose based on patient response; this may include discontinuation if seizures resolve, or increase in dose to 150mg or 200mg a day after Day 7
Study: NCT05627479

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GIK solution
Description: Therapy cocktail of Glucose, Insulin and Potassium. The medications will be prepared as per standard protocol. Administered intravenously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic Normal Saline Solution
Description: Placebo injection - administered intravenously.
Study: NCT05557357

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Description: Electroacupuncture (EA) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min.~The acupoints that will be stimulated are Tinggong (SI19) and Yifeng (TE17) of the affected side, Baihui (GV20) and Yintang (GV24+), bilateral posterior temporal line (MS11), and Zhongzhu (TE3) and Zusanli (ST36) of the affected side.~For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture Combined With Warm Needling (EAWN)
Description: Electroacupuncture combined with warm needling (EAWN) treatment following standardized procedures will be conducted for 2 sessions per week for 5 consecutive weeks. Each session of treatment will last for 25 min.~The acupoints that will be stimulated are SI19 and TE17 (affected side), GV20 and GV24+, bilateral MS11, and TE3 and ST36 (affected side).~For electroacupuncture (EA), electrical stimulation will be applied using an EA apparatus, with pairs of electrodes connecting the needles at ipsilateral SI19 and TE17, GV20 and GV24+, and bilateral MS11.~For warm needling (WN), two moxa sticks will be ignited and attached one by one to the needle handle of each acupoint of SI19 and TE17.

Intervention type: OTHER
Group type: OTHER
Intervention: Waitlist Control
Description: No treatment will be provided during the 10-week waiting period after baseline assessment.
Study: NCT06150040

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP137
Description: IV infusion, 14mg/kg or 9mg/kg, every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Injection
Description: Subcutaneous injection, 75 mg/m², on cycle Days 1-7 (28-days cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Orally, 70 mg, every day on Days 1-28
Study: NCT05147220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remibrutinib
Description: tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remibrutinib
Description: tablet taken orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remibrutinib
Description: tablet taken orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: capsule taken orally
Study: NCT06384495

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: REAL-A
Description: one session of 2mA for 20 minutes to the right ventro-lateral cerebellum

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: REAL-C
Description: one session of 2mA for 20 minutes to the right ventro-lateral cerebellum

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SHAM
Description: one session of sham tDCS for 20 minutes to the right ventro-lateral cerebellum.
Study: NCT04918420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow Diverter (Tonbridge)
Description: The device is a self-expanding vascular stent system, which consists of a stent and a delivery system. The stent is made of platinum core nickel-titanium alloy material. The delivery system is composed of a delivery guide wire and an introducer sheath. The stent and the delivery guide wire are pre-installed in the introducer sheath.
Study: NCT06068933

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: K-HEARS Intervention
Description: Tailored aural rehabilitation for participant and care partner

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: K-HEARS Intervention
Description: Tailored aural rehabilitation for participant and care partner

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: K-HEARS Intervention
Description: Tailored aural rehabilitation for participant and care partner

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: K-HEARS Sound Amplifier Intervention
Description: Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: K-HEARS Sound Amplifier Intervention
Description: Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.

Intervention type: DEVICE
Group type: OTHER
Intervention: K-HEARS Sound Amplifier Intervention
Description: Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
Study: NCT04675567

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Safety-Net Care Team Model
Description: Safety-Net Care Planning Team: Clinical expertise will be combined with peer-to-peer parent/guardian support for trauma-informed care delivery to both parent and child. All aspects of the care continuum will be provided in a culturally and linguistically competent manner, with child and family-driven care planning.
Study: NCT05671107

Intervention type: DIAGNOSTIC_TEST
Intervention: NET
Description: Online survey measuring a variety of developmental domains including anxiety, motor, daily living skills, challenging behaviors, social communication, restrictive and repetitive behaviors, ADHD, executive functioning, mood, quality of life, and sleep

Intervention type: DIAGNOSTIC_TEST
Intervention: NET
Description: Online survey measuring a variety of developmental domains including anxiety, motor, daily living skills, challenging behaviors, social communication, restrictive and repetitive behaviors, ADHD, executive functioning, mood, quality of life, and sleep

Intervention type: DIAGNOSTIC_TEST
Intervention: NET
Description: Online survey measuring a variety of developmental domains including anxiety, motor, daily living skills, challenging behaviors, social communication, restrictive and repetitive behaviors, ADHD, executive functioning, mood, quality of life, and sleep

Intervention type: DIAGNOSTIC_TEST
Intervention: NET
Description: Online survey measuring a variety of developmental domains including anxiety, motor, daily living skills, challenging behaviors, social communication, restrictive and repetitive behaviors, ADHD, executive functioning, mood, quality of life, and sleep
Study: NCT06547827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: robotic rehabilitation
Description: Treatment will occur in a gym equipped with devices for all the domains, with two physiotherapists supervising groups of 4 to 6 patients, depending on their clinical severity.~Patients will undergo a total of 25 sessions, each lasting 45 minutes, with the following frequency:~* 5 times a week for 5 weeks, for inpatients;~* 3 times a week for 8.3 weeks, for outpatients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional rehabilitation
Description: A physiotherapist-to-patient ratio of 1:1 is provided for the treatment in all participating centres.~Patients will undergo a total of 25 sessions, each lasting 45 minutes, with the following frequency:~* 5 times a week for 5 weeks, for inpatients;~* 3 times a week for 8.3 weeks, for outpatients.
Study: NCT05644119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V- loop Bonded Orthodontic Retainer
Description: The V- loop bonded retainer is a unique design that not just provides tooth stability but also allows flossing with ease.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Straight Wire Retainer
Description: The straight wire retainer is a fixed bonded orthodontic retainer. This involves attaching a metal wire to the back of the teeth to keep it in position.
Study: NCT06122688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Navigator Plus App Intervention
Description: Navigators will provide their usual care services and also be encouraged to use the Connected for Wellness (CFW) app during their usual activities with youth and caregivers at their site. The duration of this period (2, 3, or 4 years) will depend on the step period of the individual's site. All youth at the school or clinic site can use the CFW app on their own and through the app receive prevention strategies, psycho-education that destigmatizes mental health, encourages referrals to local resources as needed, and increases motivation to access care if needed.
Study: NCT04790474

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ixazomib-pomalidomide-dexamethasone
Description: Cycles 1-3: during each 21-day cycle:~* ixazomib 3 mg on Days 1, 4, 8 and 11~* pomalidomide 4 mg on Days 1 through 14~* dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16~Cycle 4 and consequently: during each 28-day cycle:~* ixazomib 4 mg on Days 1, 8 and 15~* pomalidomide 4 mg on Days 1 through 21~* dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22 and 23
Study: NCT05101590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monitored by HDA
Description: Participants undergoing elective major surgery with an arterial line as part of their standard care and additional monitoring with HDA as part of their care.
Study: NCT04913610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-4083
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-4083
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-4083
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-4083
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-4083
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-4083
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-4083
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for ABBV-4083
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Oral encapsulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Oral encapsulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Oral encapsulated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Albendazole
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Albendazole
Description: Oral Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Albendazole
Description: Oral Capsule
Study: NCT05665036

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SIG-005 (hIDUA Producing Spheres)
Description: Laparoscopic administration of SIG-005 spheres, an encapsulated allogeneic cell therapy genetically modified with a non-viral vector to produce hIDUA
Study: NCT05831033

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BEN101
Description: Lymphodepletion regimen：Cyclophosphamide 250mg/ m2/day x 3 days (day -4, -3，-2) , Fludarabine 25mg/ m2/day x 2 days (day-4, -3) , Paclitaxel 100mg/ m2/day -3. The lymphodepletion regimen could be adjusted by the treating physician according to patient's disease condition.~BEN101 infusion： Single dose level between 1x10\^9 to 1x 10\^11，not lower than 1×10\^9 cells, final dose is affected by the starting amount of TILs cells isolated from the tumor tissue sample.~IL-2：Administer 8-16 hr after TIL infusion. 600,000 IU/kg intravenously over 15-20 mins every 12 hours. It is recommended to start with high dose; and de-escalate based on tolerability, up to 5 days. IL-2 administration will be terminated if unacceptable toxicities occur.
Study: NCT06216613

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Enhanced Aquatics
Description: Sensory Enhanced Aquatics (SEA) utilizes the Sensory Profile to individualize lessons based on children's sensory preferences. The program incorporates evidence-based approaches for autistic children, including: 1) visual supports, 2) sensory supports, 3) communication strategies, 4) behavioral strategies, and 5) modeling to maximize skill acquisition. Lessons will be 1:1 with social opportunities at the beginning and end of each lesson. Like standard swim lessons, skills are taught in progression from water orientation (e.g., blowing bubbles, submerging different body parts) to advanced swimming (e.g., swimming 15 or more yards of different swim strokes). All lessons include instruction of water safety skills. Each skill has been task analyzed by therapists so instruction can be graded according to children's ability. A social story is provided to transition children to lessons. SEA curriculum was reviewed by USA Swimming Foundation and is included as a Swim Lesson Network Provider.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Swim Lessons
Description: Standard swim lessons will adhere to USA Swimming Foundation Swim Network Provider requirements ensuring lessons meet or exceed industry best practices. Lessons have up to a 1:5 instructor to child ratio and will focus on stroke development and water-safety with skills advancing from water-orientation to stroke technique and endurance.
Study: NCT05616104

Intervention type: DEVICE
Intervention: FLEX Vessel Prep System
Description: The FLEX Vessel Prep System to create circumferential, continuous micro-incisions along the length of the stenosis by performing a retrograde pullback through the lesion.~Following FLEX, standard balloon angioplasty is performed with an uncoated PTA balloon sized to meet the reference vessel diameter, according to its corresponding Instructions for Use. Once advanced into the lesion, the balloon should be inflated according to the site's standard of care.
Study: NCT04763980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Participate in educational session with health coach

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Testing
Description: Undergo genetic testing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Undergo genetic testing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Complete survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Complete survey
Study: NCT05789524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SerpinPC
Description: Administered as SC injection.
Study: NCT04519008

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile app
Description: Medical device for improving emotion dysregulation

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Bimonthly individual psychotherapy and psychostimulant medications

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Treatment as usual
Description: Bimonthly individual psychotherapy and psychostimulant medications